FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      
           
This page is updated frequently with new Platelet-related patent applications. Subscribe to the Platelet RSS feed to automatically get the update: related Platelet RSS feeds. RSS updates for this page: Platelet RSS RSS


Date/App# patent app List of recent Platelet-related patents
05/21/15
20150141477
 Pyrazole derivatives and their use as lpar5 antagonists patent thumbnailPyrazole derivatives and their use as lpar5 antagonists
The present invention relates to compounds of the formula (i), wherein the residues r1 to r5, v, g and m have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
05/21/15
20150141471
 Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation patent thumbnailPyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
The present invention relates to compounds of the formula (i), wherein the residues r1 to r6, v, g and m have the meanings indicated in the claims. The compounds of the formula i are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
05/21/15
20150141332
 Methods for diagnosing osteoarthritis patent thumbnailMethods for diagnosing osteoarthritis
Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor ab (pdgf-ab), platelet-derived growth factor bb (pdgf-bb), and epidermal growth factor (egf). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid.
Biomet Biologics, Llc
05/21/15
20150140120
 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics patent thumbnailStabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc
05/14/15
20150135344
 Methods of modulating thrombocytopenia  and modified transgenic pigs patent thumbnailMethods of modulating thrombocytopenia and modified transgenic pigs
The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided..
05/14/15
20150133446
 Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation patent thumbnailImidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
The present invention provides imidazothiadiazole compounds of formula (i) wherein a, b, d, rx, r1, r2, r3, x1, x2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments..
05/14/15
20150132261
 Treatment of thrombocytopenia using orally administered interferon patent thumbnailTreatment of thrombocytopenia using orally administered interferon
An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of ifn (about 5 iu to about 2500 iu of ifn-alpha) to a patient in need thereof.
05/14/15
20150128935
 Inhalation systems, breathing apparatuses, and methods patent thumbnailInhalation systems, breathing apparatuses, and methods
Examples of the invention include inhalation systems, breathing apparatuses, and methods for administering a solution by inhalation to a patient. Example breathing apparatuses described herein may be configured to minimize loss of the solution to the environment.
05/07/15
20150126527
 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto patent thumbnailModulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
05/07/15
20150125436
 Process, tube and device for the preparation of wound healant composition patent thumbnailProcess, tube and device for the preparation of wound healant composition
The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof..
05/07/15
20150125430

Compositions and methods for inducing thrombopoiesis


Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with livin, thereby inducing thrombopoiesis.
Hadasit Medical Research Services And Development Ltd.
05/07/15
20150122713

Prp obtaining device


A platelet rich plasma (prp) obtaining device includes a container attached to a receptacle for allowing a material in the receptacle to flow into the container, a piston engaged in the receptacle for forcing the material to partially flow into the container, a housing slidably engaged in the container and having a space and having a tube extended in the housing, the tube includes a bore communicating with a compartment of the container, but offset from the space of the housing, and a check valve is attached to the housing for limiting the material to flow only from the container to the housing, and for preventing the material from flowing backward from the housing into the container.. .
Yung Kang Medical Device & Technologic Co., Ltd.
04/30/15
20150119495

Preparation of rubber composition containing graphite platelets and tire with component


Preparation of a rubber composition containing a dispersion of aligned exfoliated graphite platelets. Such rubber composition is prepared by a method comprised of a sequential combination of concentrated solvent or dry masterbatching of elastomer and exfoliated graphite platelets, followed by blending the masterbatch (after removing the solvent from the solvent based masterbatch) with additional elastomer(s) and then followed by processing the resulting rubber composition to align the dispersed exfoliated graphite platelets in a substantially parallel relation to each other.
The Goodyear Tire & Rubber Company
04/30/15
20150119390

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i); wherein w, y, r0, r2, r4, ra, rb, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Monteal
04/30/15
20150118210

Composition for enhancing cell engraftment and homing properties containing prp as active ingredient


The present invention provides a composition for enhancing cell engraftment and homing properties, containing platelet-rich plasma (prp) as an active ingredient. The present invention provides a method for improving cell engraftment and homing properties, comprising the step of treating in vitro isolated cells with a composition containing prp as an active ingredient.
Snu R&db Foundation
04/30/15
20150118109

Component preparation system


Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system..
New York Blood Center, Inc.
04/23/15
20150111889

Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues a, r1 to r5, z1 and z2 have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
04/23/15
20150111777

Biomarker for early neurodegeneration detection


The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of tdp-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation..
Kansas City University Of Medicine And Biosciences
04/16/15
20150105338

Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation


The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (i): wherein r1, r2 and r3 may be independently selected from h, oh and ome; wherein x is c1 or c2 and wherein for c2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more h or oh, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow..
Provexis Natural Products Limited
04/16/15
20150104436

Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets


Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation.
Chang Gung Medical Foundation, Linkou Branch
04/16/15
20150101995

Device and extracting high-concentration plasma from whole blood


Disclosed are a device and method of extracting high-concentration plasma from whole blood. The device comprises: a first syringe; a centrifugation tube that is connected to the first syringe in order to centrifuge whole blood received in the first syringe; a cap that is connected to the first syringe in order to re-centrifuge plasma collected in the first syringe by centrifugation of the whole blood; and a membrane filter comprising: a body that is cylindrical in shape and has a pair of spaced inlets to which the first syringe and a second syringe are to be respectively connected; a hollow membrane included in the body; and a first space formed between the body and the membrane and serving to collect components that passed through the membrane.
04/09/15
20150099716

Maintenance of platelet inhibition during antiplatelet therapy


A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis.
The Medicines Company
04/09/15
20150099298

Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof


The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. .
Bayer Pharma Aktiengesellschaft
04/09/15
20150098939

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof


The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein glycoprotein vi (gpvi) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a gpvi depletion phenotype.
Sanofi
04/02/15
20150094298

Inhibitors of protein kinases


The present invention is directed to compounds of formula i-ii and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.
04/02/15
20150094297

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides thiazole compounds of formula i wherein w, y, r0, r2, r4, r5, r6, r7, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Montreal
04/02/15
20150093770

Method and device for the determination of platelet function under flow conditions


The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other p2y(12) antagonists with antithrombotic activity as well as the determination of p2y(1) antagonists with antithrombotic activity..
Siemens Healthcare Diagnostics Products Gmbh
04/02/15
20150093543

Blood compatible surfaces


The disclosure features blood compatible articles and methods of making the articles. The methods include providing a substrate and forming a rough surface on the substrate.
Teijin Limitied
04/02/15
20150093390

Humanized and chimeric anti-factor bb antibodies and uses thereof


A method of inhibiting complement activation mediated by bb inhibitors in a subject includes administering a bb inhibitor to the subject to inhibit at least one of bb binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Theraperutics, Inc.
03/26/15
20150083973

Systems, devices, and/or methods for solar cells comprising a light amplification element


Certain exemplary embodiments can provide a method, which can comprise fabricating a system. The system can comprise a light amplification element and a charge transport element.
K Tube Technology Llc
03/26/15
20150083355

Fibrous pulp and use thereof in a composite


A composition comprises (i) an elastomer, (ii) from 1 to 5 volume % of fibrous pulp, the pulp having a specific surface area of from 7 to 11 sq.m./g and the fiber having a fiber length of from 0.5 to 1.1 mm, a tensile modulus of from 2.5 to 130 gpa, and a tensile strength of from 1 to 3 gpa, and (iii) from 5 to 14 volume % of yield-strain promoter in the form of fibers, needles, powder or platelets, wherein the composition has a yield strain of at least 70%, an elongation at break of at least 200%, and a yield stress of at least 4 mpa.. .
E I Du Pont De Nemours And Company
03/19/15
20150080300

Growth factor concentrate and the use thereof


Provided herein are growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates comprise decapsulated growth factors derived from platelet rich plasma..
Bestop Group Holdings Limited
03/19/15
20150079194

Systems, compositions, and methods for transplantation and treating conditions


Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation
03/19/15
20150079169

Controlled dosing of clopidogrel with gastric acid inhibition therapies


The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (ppi) and optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other.
Pozen Inc.
03/19/15
20150079153

Cell suspension and use thereof


The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between.
Avita Medical Ltd.
03/19/15
20150079142

Devices and methods for preventing platelet activation


Methods for inhibiting a biomaterial-associated thrombotic event comprise reducing the number of platelets that bind to the biomaterial, or inhibiting platelet activation, by attaching cd47 or the ig domain thereof to the surface of the biomaterial. Methods of the present invention inhibit thrombi formation on or near a biomaterial that is on the surface of an implant, medical device, tube, or therapeutic delivery vehicle.
The Children's Hospital Of Philadelphia
03/19/15
20150079045

Nprcps, pfdncs and uses thereof


Identification of a group of novel particle termed “non-platelet rna-containing particles (nprcp)” provides novel compositions, downstream products and therapeutic tools. In addition a group of mixed nprcps were identified that contain rnas and proteins.
03/19/15
20150075740

Processes for clay exfoliation and uses thereof


The present invention provides methods for producing exfoliated clay platelets from a swellable clay material. In embodiments, the method for producing exfoliated clay platelets includes providing an exfoliating agent comprising an anionic extractant, and exposing the swellable clay material to the exfoliating agent, wherein the exfoliating agent produces exfoliated clay platelets from the swellable clay material.
Nanopaper, Llc
03/05/15
20150065374

Detection of platelet-derived shed cd31


The present invention relates to various soluble forms of cd31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of cd31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed cd31 and the use of such methods as a diagnostic tool..
Assistance Publique-hopitaux De Paris
03/05/15
20150064800

Diagnostic devices, methods and systems for detecting platelet factor 4 (pf4)/heparin antibodies


The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (pf4)/heparin complex in a fluid sample. The assay utilizes an immobilized pf4/polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human pf4/heparin antibodies.
03/05/15
20150064687

Method and producing platelet rich plasma


A device and method for producing a portion of platelet rich plasma from a fluid sample obtained from a patient. The device comprises three intercommunicated portions, each portion having an internal chamber defined therein.
03/05/15
20150064238

Method and composition for enhancing the delivery of anti-platelet drugs for the treatment of acute stroke


The invention provides a method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising an anti-platelet drug and a vehicle that can reduce the binding rate of plasma proteins, so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose. By use of the neuro-protective efficacy of anti-platelet drug, the invention allows the drug to release slowly to the site of treatment by combining anti-platelet drugs with a vehicle that can reduce the binding rate of plasma proteins to effectively reduce the dose of the anti-platelet drug and consequently reduce the side effects such as hypotension caused by, administration of a high dose of the anti-platelet drugs.
03/05/15
20150064202

Humanized and chimeric anti-factor c3 antibodies and uses thereof


A method of inhibiting complement activation mediated by c3b inhibitors in a subject includes administering a c3b inhibitor to the subject to inhibit at least one of c3b binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Therapeutics, Inc.
03/05/15
20150064133

Bioactive compositions derivable from platelet concentrates, and methods for preparing and using same


The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios..
Cook General Biotechnology Llc
03/05/15
20150060363

Device and processing and producing autologous platelet-rich plasma


A system and method are provided, including an integrated single-use kit, for processing whole blood to produce platelet rich plasma. A two stage spinning membrane separator, has a first stage for receiving whole blood and separating substantially all red blood cells from plasma and platelets, and a second stage for further separating platelet rich plasma from plasma.
Fenwal Inc.
03/05/15
20150059617

Cellulose platelet compositions, methods of preparing cellulose platelet compositions and products comprising same


A composition and method of preparing a composition is presented wherein the composition comprises cellulose platelets and the cellulose platelets comprise at least 60% cellulose by dry weight, less than 10% pectin by dry weight and at least 5% hemicellulose by dry weight. The composition can be concentrated to at least 25% by weight solids content by pressing under low pressure, whilst retaining the ability to be re suspended within an aqueous medium.
Cellucomp Limited
02/26/15
20150056643

Microfluidic devices for measuring platelet coagulation and associated systems and methods


The present technology relates generally to microfluidic devices for measuring platelet coagulation, and associated systems and methods. In some embodiments, a fluidics device includes an array of microstructures including pairs of generally rigid blocks and generally flexible posts.
University Of Washington Through Its Center For Commercialization
02/26/15
20150056604

Compositions and methods for preserving platelet function


Compositions and methods for maintaining platelet functionality and extending the shelf-life of platelets are described. Platelet preservation compositions include a photosensitizer and a plurality of platelet preservation agents.
Biovec Transfusion, Llc
02/26/15
20150056602

Apheresis platelets with fixed residual plasma volume


Methods and systems for obtaining platelets are disclosed. Platelets are collected in a pre-determined volume of plasma and a determined amount of a combined storage medium including the pre-determined amount of plasma and a volume of a synthetic additive solution..
Fenwal, Inc.
02/26/15
20150052723

Methods and systems for fabricating platelets of a monochromator for x-ray photoelectron spectroscopy


Methods and systems for fabricating platelets of a monochromator for x-ray photoelectron spectroscopy (xps) are disclosed. For example, a method of fabricating a platelet of a monochromator for x-ray photoelectron spectroscopy involves placing a crystal on a stage of an x-ray measuring apparatus, the crystal having a top surface.
02/19/15
20150050677

Methods and systems for measuring whole blood platelet reactivity


The invention relates to a novel approach and related methods and systems, which provide accurate and easily implemented measurement and analyses of whole blood platelet reactivity, and impact on treatment thereof.. .
University Of Massachusetts Medical School
02/19/15
20150050641

Method for the enumeration of mammalian micronucleated erythrocyte populations, while distinguishing platelets and/or platelet-associated aggregates


A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains dna (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
Litron Laboratories, Ltd.
02/19/15
20150050331

Method for making a topical composition comprising growth factors derived from human umbilical cord blood platelets


The present invention is directed to a method of making a stable composition comprising growth factors, which may include platelet derived growth factors and transforming growth factors. The method comprises providing human umbilical cord blood plasma containing platelets, but substantially free of whole blood cells, and lysing the platelets to extrude growth factors into the plasma.
Novo Solutions Md, Llc
02/19/15
20150050325

Organic compounds


The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery..
The Rockefeller University


Popular terms: [SEARCH]

Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.4786

3288

1 - 1 - 71